Halozyme Therapeutics (NASDAQ:HALO) Given New $81.00 Price Target at JPMorgan Chase & Co.

Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its target price upped by JPMorgan Chase & Co. from $79.00 to $81.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the stock. Citizens Jmp upped their price target on shares of Halozyme Therapeutics from $93.00 to $149.00 and gave the stock a “market outperform” rating in a research note on Friday, November 6th. Zacks Research lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 11th. Wedbush set a $130.00 target price on shares of Halozyme Therapeutics in a report on Friday. Stifel Nicolaus set a $130.00 price target on Halozyme Therapeutics in a report on Friday, October 16th. Finally, TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Monday. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $110.17.

Check Out Our Latest Report on Halozyme Therapeutics

Halozyme Therapeutics Stock Down 1.8%

HALO opened at $91.35 on Friday. The company’s 50-day moving average price is $113.21 and its two-hundred day moving average price is $86.03. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $134.00. The stock has a market cap of $10.41 billion, a price-to-earnings ratio of 17.33, a PEG ratio of 0.36 and a beta of 0.92. The company has a quick ratio of 3.60, a current ratio of 3.88 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The company had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. During the same period last year, the business earned $1.72 earnings per share. Halozyme Therapeutics’s revenue was up 39.1% compared to the same quarter last year. As a group, equities analysts expect that Halozyme Therapeutics will post 8.34 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $98.38, for a total transaction of $1,967,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $75,534,196.40. The trade was a 2.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 18th. The stock was sold at an average price of $96.43, for a total value of $482,150.00. Following the transaction, the director owned 48,609 shares of the company’s stock, valued at approximately $4,687,365.87. This represents a 9.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 149,226 shares of company stock valued at $15,744,643 in the last 90 days. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of HALO. Bank of America Corp DE acquired a new stake in Halozyme Therapeutics in the second quarter valued at $214,504,000. William Blair Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $196,540,000. Congress Asset Management Co. raised its holdings in Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after buying an additional 1,052,509 shares during the period. Groupama Asset Managment acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at about $2,630,000. Finally, First Trust Advisors LP grew its stake in shares of Halozyme Therapeutics by 28.3% during the third quarter. First Trust Advisors LP now owns 1,817,824 shares of the biopharmaceutical company’s stock valued at $200,688,000 after acquiring an additional 400,761 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Halozyme Therapeutics

These are some of the HALO headlines that stood out recently:

  • Positive Sentiment: HC Wainwright reaffirmed its buy rating and set a $130 price target, suggesting substantial upside from the cited share price. HC Wainwright ratings
  • Neutral Sentiment: JPMorgan raised its target to $81 from $79 but maintained a neutral rating; the new target is below the cited share price, signaling a more cautious view. JPMorgan ratings
  • Negative Sentiment: A German court overturned the preliminary injunction that had blocked Merck from offering its subcutaneous Keytruda product in Germany. Halozyme says it will pursue a permanent patent case, but the ruling removes an immediate barrier to Merck’s launch and adds uncertainty to the dispute’s potential commercial impact. Report on German court ruling

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

See Also

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.